ArticleJACC. Advances2024
Digital Twin in Managing Hypertension Among People With Type 2 Diabetes: 1-Year Randomized Controlled Trial.
Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Digital Twin Applications in Diabetes Management: Scoping Review.JMIR diabetes · 2026Review
- Human digital twins in women's health nursing.Women's health nursing (Seoul, Korea) · 2026Article
- Development of the Windmill Model for Mapping Older Adults' Intrinsic Capacity Using Digital Twin Technology: Descriptive Qualitative Study.JMIR aging · 2026Article
- Exploring Professionals' Perceptions of the Potential of Digital Twins in Homecare-A Focus Group Study in Sweden.Healthcare (Basel, Switzerland) · 2026Article
- Analysis of digital twin applications in nursing practice and education: a scoping review.Journal of educational evaluation for health professions · 2026Article
- A digital twin framework for predicting and simulating type 2 diabetes onset using retrospective lifestyle data.Frontiers in digital health · 2026Article
- Cardiometabolic risk reduction with digital twinning in patients with type 2 diabetes.Cardiovascular diabetology. Endocrinology reports · 2025Review
- Artificial Intelligence for Cardiovascular Care in Action: From Learning to Implementation in Health Systems.JACC. Advances · 2025Review
- From Architecture to Outcomes: Mapping the Landscape of Digital Twins for Personalized Diabetes Care-A Scoping Review.Journal of personalized medicine · 2025Review
- Artificial Intelligence Enabled Lifestyle Medicine in Diabetes Care: A Narrative Review.American journal of lifestyle medicine · 2025Review
- Applications, technical foundations and challenges of digital twins for chronic disease management: A scoping review.Digital healthReview
- Unveiling the potential of digital twins in homecare: A reflexive thematic analysis of older adults' views.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digital twin (DT)-guided lifestyle changes induce type 2 diabetes (T2D) remission but effects on hypertension (HTN) in this population are unknown. Objectives: The purpose of this study was to assess effects of DT vs standard of care (SC) on blood pressure (BP), anti-HTN medication, HTN remission, and microalbuminuria in participants with T2D. Methods: This is a secondary analysis of a randomized controlled trial in India of 319 participants with T2D. Participants were randomized to DT group (N = 233), which used artificial intelligence-enabled DT technology, or SC group (N = 86). A Home Blood Pressure Monitoring system guided anti-HTN medication adjustments. BP, anti-HTN medications, HTN remission rates, and microalbuminuria were compared between groups. Results: Among the 319 participants, 44 in DT and 15 in SC group were on anti-HTN medications, totaling 59 (18.4%) participants. DT group achieved significant reductions in systolic blood pressure (-7.6 vs -3.2 mm Hg; Conclusions: Artificial intelligence -enabled DT technology is more effective than SC in reducing BP and anti-HTN medications and inducing HTN remission and normoalbuminuria in participants with HTN and T2D. (A Novel WholeBody Digital Twin Enabled Precision Treatment for Reversing Diabetes; CTRI/2020/08/027072).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.